You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
|
|---|---|
| Published in |
BMC Pulmonary Medicine, January 2014
|
| DOI | 10.1186/1471-2466-14-4 |
| Pubmed ID | |
| Authors |
Kenneth R Chapman, Kai-Michael Beeh, Jutta Beier, Eric D Bateman, Anthony D’Urzo, Robert Nutbrown, Michelle Henley, Hungta Chen, Tim Overend, Peter D’Andrea |
| Abstract |
Two once-daily long-acting muscarinic antagonists (LAMAs) are currently available for the treatment of chronic obstructive pulmonary disease (COPD) - tiotropium and glycopyrronium. Previous studies have compared glycopyrronium with open-label tiotropium. In the GLOW5 study, we compare glycopyrronium with blinded tiotropium. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 25% |
| United States | 1 | 13% |
| Switzerland | 1 | 13% |
| United Kingdom | 1 | 13% |
| Unknown | 3 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Scientists | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| Portugal | 1 | <1% |
| Unknown | 113 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 16% |
| Student > Master | 15 | 13% |
| Student > Bachelor | 15 | 13% |
| Other | 12 | 10% |
| Student > Postgraduate | 10 | 9% |
| Other | 23 | 20% |
| Unknown | 23 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 47% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 9% |
| Agricultural and Biological Sciences | 5 | 4% |
| Nursing and Health Professions | 5 | 4% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Other | 9 | 8% |
| Unknown | 29 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2018.
All research outputs
#3,688,216
of 22,953,506 outputs
Outputs from BMC Pulmonary Medicine
#255
of 1,941 outputs
Outputs of similar age
#44,453
of 305,774 outputs
Outputs of similar age from BMC Pulmonary Medicine
#6
of 26 outputs
Altmetric has tracked 22,953,506 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,941 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,774 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.